|
Molecular
Devices to distribute ChanTest’s cell lines
May 2011
SHARING OPTIONS:
SUNNYVALE,
Calif.—Molecular Devices Inc. and ChanTest Corp.
recently signed an agreement whereby Molecular Devices
will distribute
ChanTest's portfolio of more than 145 ion channel and 110 GPCR cell lines on a
non-exclusive basis. Under the agreement, Molecular
Devices will sell
ChanTest's ion channel and GPCR cell lines, in addition to promoting ChanTest's
cell optimization services. Mark Verheyden,
president of Molecular Devices,
says the distribution agreement allows Molecular Devices "to provide our
customers a complete end-to-end solution for
their ion channel and GPCR
assays." Dr. Arthur Brown, founder of ChanTest, adds that "the ability to
screen ion channels with automated
electrophysiology is revolutionizing drug
discovery." No financial details regarding the agreement were disclosed.
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|